CBS 2019
CBSMD教育中心
English

动脉粥样硬化性心血管疾病

科研文章

荐读文献

2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD ESC Clinical Practice Guidelines Short-Term Progression of Multiterritorial Subclinical Atherosclerosis Colchicine Reduces Cardiovascular Events in Chronic Coronary Disease Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial Prognostic value of coronary artery calcium screening in subjects with and without diabetes Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar Long-term effects of intensive glucose lowering on cardiovascular outcomes Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Review ArticleVolume 75, Issue 20, May 2020

JOURNAL:JACC Article Link

Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review

L Cho, M Davis, and for the ACC CVD Womens Committee Members. Keywords: adverse pregnancy outcomes; aspirin; atrial fibrillation; cardiovascular disease; gestational diabetes

ABSTRACT

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality for women in the United States and worldwide. There has been no American College of Cardiology (ACC)/American Heart Association guideline update specifically for the prevention of CVD in women since 2011. Since then, the body of sex-specific data has grown, in addition to updated hypertension, cholesterol, diabetes, atrial fibrillation, and primary prevention guidelines. The ACC CVD in Women Committee undertook a review of the recent guidelines and major studies to summarize recommendations pertinent to women. In this update, the authors address special topics, particularly the risk factors and treatments that have led to some controversies and confusion. Specifically, sex-related risk factors, hypertension, diabetes, hyperlipidemia, anticoagulation for atrial fibrillation, use of aspirin, perimenopausal hormone therapy, and psychosocial issues are highlighted.